Quantcast

Latest Cytochrome P450 Stories

2010-03-17 16:21:29

Providing key knowledge about drug toxicity and effectiveness New Orleans, LA "“ Research led by Wayne L. Backes, PhD, Professor of Pharmacology and Associate Dean for Research at LSU Health Sciences Center New Orleans School of Medicine, has found that drug metabolism depends not only upon which enzymes are present in an individual, but also how they interact, and that can be the difference in whether a drug is safely eliminated from the body or is converted into a toxic or...

2009-10-20 06:00:00

FRANKLIN LAKES, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS) today announced it will conduct a head-to-head study of Plavix® (clopidogrel) and Effient® (prasugrel) that measures how the effectiveness of these drugs in heart patients is impacted by their genetic make-up. The study will examine whether the 70 to 75 percent of patients who are "extensive metabolizers" of clopidogrel - because they were born with a...

2009-05-05 06:00:00

TOKYO and INDIANAPOLIS, Ind., May 5 /PRNewswire-FirstCall/ -- A new substudy from 1,466 patients from the Phase III TRITON-TIMI 38 clinical trial showed that patients who took prasugrel and had a reduced function of the CYP2C19 gene did not have an increased risk of cardiovascular death, heart attack or stroke compared with those patients who had normal function. The substudy results were published online in Circulation on May 4, 2009(1). Prasugrel is a "prodrug" that requires the use of...

2009-01-22 06:00:00

CARLSBAD, Calif., Jan. 22 /PRNewswire/ -- AutoGenomics, a leader in providing automated molecular testing solutions announced today that its CYP450 2C19 assay was used in a study to demonstrate the value of genetic variants in dosing of the antiplatelet agent, Plavix. Plavix, commonly known as Clopidogrel, is an anti-platelet agent used in the treatment for coronary artery disease, peripheral vascular disease and cerebrovascular disease. To realize the...

2008-12-15 00:04:38

Dense breast tissue contains more cells believed to give rise to breast cancer, compared to non-dense tissue, U.S. researchers said. Dr. Karthik Ghosh, a Mayo Clinic breast cancer researcher, said researchers found a dramatic difference in tissue composition between dense and non-dense tissue in the breast. In a second study, Celine Vachon, also of the Mayo Clinic, found that dense breast tissue has more aromatase enzyme than non-dense tissue. This is significant because aromatase helps...

2008-11-05 09:00:34

Osmetech, a molecular diagnostics company, has launched a new genetic test for CYP450 2C9 drug metabolism. The CYP2C9 gene is important in its involvement in the metabolism of 10% of all drugs, including non-steroidal anti-inflammatory drugs (eg celecoxib, ibuprofen), anti-coagulants (eg warfarin), anti-epileptic agents (eg phenytoin), cholesterol-lowering drugs (statins / eg fluvastatin) and anti-diabetic agents (eg aprepitant). CYP2C9 polymorphisms result in a decrease or loss of enzyme...

2008-11-04 09:00:30

Osmetech plc (LSE:OMH), the international molecular diagnostics company announces the launch of a genetic test for CYP450 2C9 drug metabolism. CYP450 2C9, or CYP2C9, is an important member of the Cytochrome P450 family of enzymes responsible for detoxifying potentially hazardous chemicals, such as drugs, that are "foreign" to the body. The CYP2C9 gene is important in its involvement in the metabolism of 10% of all drugs, including non-steroidal anti-inflammatory drugs (e.g. celecoxib,...

2008-10-01 03:00:07

By Chaudhry, A S Kochhar, R; Kohli, K K Proton pump inhibitors (PPIs) are extensively metabolized in the liver by CYP2C19, that demonstrates genetic polymorphism with 21 mutant alleles. The subjects can be divided into 2 groups with respect to CYP2C19 phenotypes viz., extensive metabolizers (EMs) and poor metabolizers (PMs) of PPIs. This division results in marked interindividual variations in the pharmacokinetics and pharmacodynamics of PPIs in the population. Intragastric pH values and...

2008-03-06 15:01:15

Research and Markets (http://www.researchandmarkets.com/reports/c84902) has announced the addition of The Biochemistry of Drug Metabolism: Principles, Redox Reactions, Hydrolyses to their offering. The first of the two volumes is divided into three parts. Part One begins by introducing xenobiotics in the broad context of physiological metabolism, and continues with an overview of the processes of drug disposition and metabolism. It then goes on to summarize the macroscopic and...

2007-06-12 03:00:10

By Masubuchi, Yasuhiro Horie, Toshiharu Cytochrome P450 (P450) enzymes oxidize xenobiotics into chemically reactive metabolites or intermediates as well as into stable metabolites. If the reactivity of the product is very high, it binds to a catalytic site or sites of the enzyme itself and inactivates it. This phenomenon is referred to as mechanism-based inactivation. Many clinically important drugs are mechanism-based inactivators that include macrolide antibiotics, calcium channel...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related